Very important changes in the field of AML and MDS have been presented at the meeting and have very recently been published in top journals. First of all, the new M-IPSS integrating molecular analysis in a prognostic score for MDS was discussed by Elli Papaemmanuil and published by Elsa Bernard in June 2022 in NEJM Evid.1 Secondly, the fifth edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms was published by J. Khoury.2 It introduced new entities in MDS and AML. Finally, the updated ELN (European Leukemia Net) guidelines for diagnosis and management of AML were published in Blood in July 2022 by Hartmut Döhner.3 The impact of these three 2022 publications on the management of MDS and AML cannot be overestimated. They are not part of this report but we strongly recommend reading these papers as a background. This report is focussing on the abstracts with potential clinical impact on the treatment of AML or MDS.
(BELG J HEMATOL 2022;13(5):190–9)